WO2023002872A1 - 皮膚浸透用化粧料 - Google Patents
皮膚浸透用化粧料 Download PDFInfo
- Publication number
- WO2023002872A1 WO2023002872A1 PCT/JP2022/027174 JP2022027174W WO2023002872A1 WO 2023002872 A1 WO2023002872 A1 WO 2023002872A1 JP 2022027174 W JP2022027174 W JP 2022027174W WO 2023002872 A1 WO2023002872 A1 WO 2023002872A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- component
- group
- skin
- mass
- cosmetic
- Prior art date
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 32
- 150000005846 sugar alcohols Polymers 0.000 claims abstract description 28
- 239000002280 amphoteric surfactant Substances 0.000 claims abstract description 23
- 150000003672 ureas Chemical class 0.000 claims abstract description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000004202 carbamide Substances 0.000 claims abstract description 9
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 8
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 60
- 235000005152 nicotinamide Nutrition 0.000 claims description 48
- 239000011570 nicotinamide Substances 0.000 claims description 48
- 229960003966 nicotinamide Drugs 0.000 claims description 45
- 239000004615 ingredient Substances 0.000 claims description 22
- 239000000203 mixture Substances 0.000 claims description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 17
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 17
- 239000000811 xylitol Substances 0.000 claims description 17
- 235000010447 xylitol Nutrition 0.000 claims description 17
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 17
- 229960002675 xylitol Drugs 0.000 claims description 17
- 230000035515 penetration Effects 0.000 claims description 12
- -1 isostearyl group Chemical group 0.000 claims description 11
- MRIXVKKOHPQOFK-UHFFFAOYSA-N 4-methoxysalicylic acid Chemical compound COC1=CC=C(C(O)=O)C(O)=C1 MRIXVKKOHPQOFK-UHFFFAOYSA-N 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 235000011187 glycerol Nutrition 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- IZZIWIAOVZOBLF-UHFFFAOYSA-N 5-methyloxysalicylic acid Natural products COC1=CC=C(O)C(C(O)=O)=C1 IZZIWIAOVZOBLF-UHFFFAOYSA-N 0.000 claims description 5
- 125000001165 hydrophobic group Chemical group 0.000 claims description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 4
- CLAHOZSYMRNIPY-UHFFFAOYSA-N 2-hydroxyethylurea Chemical compound NC(=O)NCCO CLAHOZSYMRNIPY-UHFFFAOYSA-N 0.000 claims description 4
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 claims description 4
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- GYDJEQRTZSCIOI-LJGSYFOKSA-N tranexamic acid Chemical compound NC[C@H]1CC[C@H](C(O)=O)CC1 GYDJEQRTZSCIOI-LJGSYFOKSA-N 0.000 claims description 4
- 229960000401 tranexamic acid Drugs 0.000 claims description 4
- HBAIZGPCSAAFSU-UHFFFAOYSA-N 1-(2-hydroxyethyl)imidazolidin-2-one Chemical compound OCCN1CCNC1=O HBAIZGPCSAAFSU-UHFFFAOYSA-N 0.000 claims description 3
- 239000004386 Erythritol Substances 0.000 claims description 3
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 3
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 3
- 235000019414 erythritol Nutrition 0.000 claims description 3
- 229940009714 erythritol Drugs 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 claims description 2
- 229940043375 1,5-pentanediol Drugs 0.000 claims description 2
- PRNCMAKCNVRZFX-UHFFFAOYSA-N 3,7-dimethyloctan-1-ol Chemical group CC(C)CCCC(C)CCO PRNCMAKCNVRZFX-UHFFFAOYSA-N 0.000 claims description 2
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical group CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 108010008488 Glycylglycine Proteins 0.000 claims description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 229940043257 glycylglycine Drugs 0.000 claims description 2
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 239000000845 maltitol Substances 0.000 claims description 2
- 235000010449 maltitol Nutrition 0.000 claims description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 2
- 229940035436 maltitol Drugs 0.000 claims description 2
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims description 2
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 229960002920 sorbitol Drugs 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 235000013877 carbamide Nutrition 0.000 claims 1
- 229960005150 glycerol Drugs 0.000 claims 1
- 229960004063 propylene glycol Drugs 0.000 claims 1
- 235000013772 propylene glycol Nutrition 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 92
- 239000004480 active ingredient Substances 0.000 description 31
- DVEKCXOJTLDBFE-UHFFFAOYSA-N n-dodecyl-n,n-dimethylglycinate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC([O-])=O DVEKCXOJTLDBFE-UHFFFAOYSA-N 0.000 description 30
- 210000000434 stratum corneum Anatomy 0.000 description 24
- 239000002904 solvent Substances 0.000 description 22
- 238000002360 preparation method Methods 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 230000001186 cumulative effect Effects 0.000 description 15
- 238000002156 mixing Methods 0.000 description 14
- 239000007788 liquid Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 230000004907 flux Effects 0.000 description 12
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 11
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
- 239000002953 phosphate buffered saline Substances 0.000 description 10
- YRJKYHIIYRGTCC-UHFFFAOYSA-M potassium;2-hydroxy-4-methoxybenzoate Chemical compound [K+].COC1=CC=C(C([O-])=O)C(O)=C1 YRJKYHIIYRGTCC-UHFFFAOYSA-M 0.000 description 10
- 239000006185 dispersion Substances 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000004888 barrier function Effects 0.000 description 6
- 238000009792 diffusion process Methods 0.000 description 6
- 229940094506 lauryl betaine Drugs 0.000 description 6
- 239000006210 lotion Substances 0.000 description 6
- 231100000245 skin permeability Toxicity 0.000 description 6
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 229960003237 betaine Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 4
- XPALGXXLALUMLE-UHFFFAOYSA-N 2-(dimethylamino)tetradecanoic acid Chemical compound CCCCCCCCCCCCC(N(C)C)C(O)=O XPALGXXLALUMLE-UHFFFAOYSA-N 0.000 description 4
- 239000000823 artificial membrane Substances 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 3
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 3
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 3
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 3
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 3
- 101100346656 Drosophila melanogaster strat gene Proteins 0.000 description 3
- YJYPHIXNFHFHND-UHFFFAOYSA-N agomelatine Chemical compound C1=CC=C(CCNC(C)=O)C2=CC(OC)=CC=C21 YJYPHIXNFHFHND-UHFFFAOYSA-N 0.000 description 3
- 229960002629 agomelatine Drugs 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000003961 penetration enhancing agent Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 2
- NPKLJZUIYWRNMV-UHFFFAOYSA-N 2-[decyl(dimethyl)azaniumyl]acetate Chemical compound CCCCCCCCCC[N+](C)(C)CC([O-])=O NPKLJZUIYWRNMV-UHFFFAOYSA-N 0.000 description 2
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 241000209094 Oryza Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229960003589 arginine hydrochloride Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000000245 forearm Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 239000002608 ionic liquid Substances 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000037307 sensitive skin Effects 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NSZGZRADTSQJIW-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-4,5,6-trimethylpyrimidine Chemical compound N1=C(C)C=C(C)N1C1=NC(C)=C(C)C(C)=N1 NSZGZRADTSQJIW-UHFFFAOYSA-N 0.000 description 1
- HZNGLSIEGWQEIB-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-4,6-dimethylpyrimidine Chemical compound N1=C(C)C=C(C)N1C1=NC(C)=CC(C)=N1 HZNGLSIEGWQEIB-UHFFFAOYSA-N 0.000 description 1
- HVYJSOSGTDINLW-UHFFFAOYSA-N 2-[dimethyl(octadecyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O HVYJSOSGTDINLW-UHFFFAOYSA-N 0.000 description 1
- KKMIHKCGXQMFEU-UHFFFAOYSA-N 2-[dimethyl(tetradecyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O KKMIHKCGXQMFEU-UHFFFAOYSA-N 0.000 description 1
- AMRBZKOCOOPYNY-QXMHVHEDSA-N 2-[dimethyl-[(z)-octadec-9-enyl]azaniumyl]acetate Chemical compound CCCCCCCC\C=C/CCCCCCCC[N+](C)(C)CC([O-])=O AMRBZKOCOOPYNY-QXMHVHEDSA-N 0.000 description 1
- TYIOVYZMKITKRO-UHFFFAOYSA-N 2-[hexadecyl(dimethyl)azaniumyl]acetate Chemical compound CCCCCCCCCCCCCCCC[N+](C)(C)CC([O-])=O TYIOVYZMKITKRO-UHFFFAOYSA-N 0.000 description 1
- MJSIJVNFECKIPK-UHFFFAOYSA-N 2-hydroxyethylurea Chemical compound NC(=O)NCCO.NC(=O)NCCO MJSIJVNFECKIPK-UHFFFAOYSA-N 0.000 description 1
- LVARGXCJOVOLKD-UHFFFAOYSA-N 5-ethyl-2-(4-ethyl-3,5-dimethylpyrazol-1-yl)-4,6-dimethylpyrimidine Chemical compound CC1=C(CC)C(C)=NN1C1=NC(C)=C(CC)C(C)=N1 LVARGXCJOVOLKD-UHFFFAOYSA-N 0.000 description 1
- WTFUTSCZYYCBAY-SXBRIOAWSA-N 6-[(E)-C-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-N-hydroxycarbonimidoyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C/C(=N/O)/C1=CC2=C(NC(O2)=O)C=C1 WTFUTSCZYYCBAY-SXBRIOAWSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 240000000300 Zizania aquatica Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- FDVKPDVESAUTEE-UHFFFAOYSA-N hexane-1,6-diol;2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O.OCCCCCCO FDVKPDVESAUTEE-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 229940031575 hydroxyethyl urea Drugs 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940035429 isobutyl alcohol Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- FQPSGWSUVKBHSU-UHFFFAOYSA-N methacrylamide Chemical compound CC(=C)C(N)=O FQPSGWSUVKBHSU-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the present invention relates to cosmetics for skin penetration.
- Patent Document 1 for the purpose of realizing rapid percutaneous absorption of agomelatine, agomelatine containing agomelatine, dimethylisosorbide or N-methyl-2-pyrrolidone, and a fatty acid having 2 to 22 carbon atoms is disclosed.
- a tape agent is described, and the addition of glycerin and a fatty acid-based ionic liquid is also described.
- Patent Document 2 describes a skin preparation for external use, which consists of an ionic water-soluble drug such as an antiepileptic drug and an amphoteric surfactant, and which enhances the percutaneous absorbability of the ionic water-soluble drug.
- an ionic water-soluble drug such as an antiepileptic drug and an amphoteric surfactant
- one aspect of the present invention provides a skin-penetrating cosmetic that is excellent in percutaneous absorbability of a skin condition-improving ingredient, and in particular allows the skin condition-improving ingredient to penetrate satisfactorily into the skin.
- the challenge is to
- an alkylbetaine-based amphoteric surfactant (b) one or more selected from the group consisting of polyhydric alcohols, urea, and urea derivatives, (c ) a skin condition-improving ingredient and (d) water.
- a skin-penetrating cosmetic that is excellent in percutaneous absorbability of a skin condition-improving ingredient, and in particular allows the skin condition-improving ingredient to penetrate satisfactorily into the skin.
- FIG. 1 is a graph showing the results of Examples 1-1 to 1-3.
- 2 is a graph showing the results of Examples 2-1 to 2-3.
- 3 is a graph showing the results of Examples 3-1 to 3-3.
- FIG. 10 is a graph showing the cumulative permeation amount results of Examples 4-1 and 4-2.
- FIG. 4 is a graph showing the results for flux of Examples 4-1 and 4-2.
- FIG. 10 is a graph showing the cumulative permeation amount results of Examples 4-3 and 4-4.
- FIG. FIG. 4 is a graph showing the results for flux of Examples 4-3 and 4-4.
- FIG. Fig. 4 is a graph showing the results for the distribution of active ingredients in the skin of Examples 4-1 and 4-2.
- FIG. 4 is a graph showing the results for the distribution of active ingredients in the skin of Examples 4-3 and 4-4.
- 4 is a graph showing the results for permeation of potassium 4-methoxysalicylate of Examples 4A-1 and 4A-2.
- FIG. 4 is a graph showing results for penetration of tranexamic acid in Examples 4-3 and 4-4.
- FIG. 10 is a graph showing the cumulative permeation amount results of Examples 5-1 to 5-10.
- FIG. FIG. 10 is a graph showing results for fluxes of Examples 5-1 to 5-10.
- skin permeation refers not only to the incorporation of a predetermined component into the skin, but also to the diffusion of the predetermined component into the skin. Therefore, when it is said that the skin permeability is high, in addition to the fact that the prescribed component is easily absorbed into the skin, it means that the prescribed component is likely to remain in the skin (also referred to as skin retentivity).
- cosmetics may be cosmetics or quasi-drugs, preferably in the form of skin care products such as lotion, milky lotion, and serum, or basic cosmetics. It may also be in the form of personal care products (daily hygiene products) such as hair conditioners, hand creams, body creams, and body lotions. Cosmetics may be in the form of lotions, creams, emulsions, gels, or balms, or may be in the form of foams that are mixed with gas such as air or that are mixed and discharged. . In addition, in the case of an emulsion, it may be oil-in-water type, water-in-oil type, or other forms.
- the skin-penetrating cosmetic composition according to the present embodiment uses a solvent obtained by combining a betaine-based amphoteric surfactant with at least one of polyhydric alcohol, urea, and urea derivatives to provide skin-lightening agents and anti-aging agents. It improves the percutaneous absorbability, particularly the skin permeability, of the condition-improving ingredients (active ingredients, which will be described in detail later).
- the skin has a function (barrier function) to prevent foreign substances from entering the body (barrier function), and it is known that most of the barrier function is performed by the stratum corneum, which is the outermost layer.
- the cosmetic having the composition of this form is quickly taken into the skin, and in particular can rapidly penetrate the stratum corneum, and is rapidly delivered to the epidermis below the stratum corneum (also referred to as the sub-stratum corneum) and the dermis. obtain. Furthermore, it can remain in the substratum corneum and dermis for a period of time during which the action of the skin condition-improving ingredient is exhibited satisfactorily.
- the solvent causes little or no damage to the skin, so it can be applied over a relatively large area, and the skin-improving ingredient can exert its function over a wide area of the skin. can.
- Component (a) is a solvent that functions as a penetration enhancer for the skin condition improving component in combination with component (b) described below.
- Component (a) is an alkylbetaine type of surfactant betaine compounds. More specifically, component (a) is
- R 3 is an alkyl group having 10 to 18 carbon atoms
- R 4 and R 5 are each independently an alkyl group having 1 to 3 carbon atoms.
- component (a) preferably has a hydrophobic group with 10 to 18 carbon atoms, more preferably a linear alkyl group with 10 to 18 carbon atoms. Having such a hydrophobic group makes the cosmetic more compatible with the skin when applied to the skin, thereby improving the percutaneous absorbability, especially the skin permeability, of the cosmetic and the skin condition improving ingredient. improves.
- hydrophobic group examples include cholesteryl group, oleyl group, isostearyl group, stearyl group, isopalmityl group, myristyl group, lauryl group, caprin group, pelargol group, capryl group, caproyl group, ⁇ -rylorenyl group, A stearyl group, an eicosapentaenoyl group, a docosahexaenyl group, and the like can be mentioned.
- component (a) alkylbetaine-based amphoteric surfactants include laurylbetaine (betaine lauryldimethylaminoacetate), myristylbetaine, cetylbetaine, stearylbetaine, caprylbetaine, pelargolbetaine, isostearylbetaine, oleylbetaine, and the like. is mentioned. Of these, lauryl betaine and capryl betaine are preferred in consideration of their action on the stratum corneum.
- the component (a) may be added and contained in the form of a salt in the skin-penetrating cosmetic according to the present embodiment.
- the salt may be an alkali metal salt or an alkaline earth metal salt, preferably the sodium salt.
- the content of component (a) with respect to the total amount of the skin-penetrating cosmetic according to this embodiment is preferably 0.001% by mass or more and 10% by mass or less, more preferably 0.1% by mass or more and 1% by mass or less. good.
- Component (b) is a component which, in combination with component (a), functions as a penetration enhancer for the skin condition-improving component.
- Component (b) can be a polyhydric alcohol, urea, or a urea derivative, or a combination thereof.
- component (b) acts as a solvent for the skin condition-improving component, exhibits a stratum corneum fluidization action, and exhibits a good permeation promoting action. It also has the advantage of causing little or no irritation to the skin (e.g. unpleasant effects perceived by the user as symptoms such as pain, itching, rashes, redness, etc.) and can be used even on sensitive skin.
- component (b) when the component (b) is a polyhydric alcohol, it may be a divalent to decavalent aliphatic alcohol, preferably a trivalent to hexavalent linear or cyclic aliphatic alcohol.
- Component (b) is preferably a sugar alcohol.
- the number of carbon atoms in the polyhydric alcohol is preferably 3 or more and 8 or less.
- component (b) is a polyhydric alcohol
- specific examples include propylene glycol, 1,3-butylene glycol, pentanediol, pentylene glycol, hexanediol, hexylene glycol (2-methyl-2,4- pentanediol), isoprene glycol (3-methyl-1,3-butanediol), glycerol (glycerin), diglycerol (diglycerin), erythritol, xylitol, sorbitol, maltitol, polyethylene glycol and the like.
- These polyhydric alcohols can be used alone or in combination of two or more.
- xylitol can form a stable structure by forming a hydrogen bond with the component (a), has a high affinity with the component (a), or has a high miscibility with the component (a). preferable.
- the component (b) is a urea derivative
- specific examples thereof include 2-hydroxyethyl urea (Hydrovanece (registered trademark), etc.), arginine salts such as arginine hydrochloride (arginine hydrochloride), and the like.
- These urea derivatives can be used alone or in combination of two or more.
- 2-hydroxyethyl urea N-hydroxyethyl urea
- 2-hydroxyethyl urea N-hydroxyethyl urea
- the content of component (b) with respect to the total amount of the skin-penetrating cosmetic according to this embodiment is preferably 0.01% by mass or more and 10% by mass or less, more preferably 0.1% by mass or more and 1% by mass or less. good.
- the content of component (b) acts to appropriately reduce the barrier function of the stratum corneum together with component (a) described above, dissolves the skin condition improving component, and improves skin condition. It is possible to improve the percutaneous absorbability of the improving component.
- the content of component (a) is 10% by mass or less, it is possible to prevent the amount of polyhydric alcohol from becoming excessively large and lowering the usability of the cosmetic composition.
- Component (a) and component (b) may greatly lower the melting point of the resulting mixture due to intermolecular interaction when mixed. For example, even if both are solid at normal temperature, they may be changed into liquid or amorphous state (amorphous) at normal temperature by mixing.
- Component (a) and component (b) in this embodiment form a complex by combining, and can constitute what is called a deep eutectic solvent (DES) or an ionic liquid (Ion Liquid; IL). .
- DES deep eutectic solvent
- Ion Liquid ionic liquid
- a liquid solvent obtained by mixing a plurality of components in this way and having a melting point lower than that of the components before mixing is sometimes referred to as a composite solvent.
- the skin condition improving component (component (c) described later) in the cosmetic is can be readily absorbed into the skin. This is probably because the combination of component (a) and component (b) denatures the stratum corneum, which is the outermost layer of the skin, to some extent, thereby reducing the barrier function.
- the combination of component (a) and component (b) can lengthen the residence time of the dissolved skin condition improving component in the skin.
- component (a) and component (b) can dissolve the skin condition improving component at an appropriate concentration.
- Some skin condition-improving ingredients are difficult to dissolve in solvents commonly used in the field of cosmetics, but by using the combination of component (a) and component (b) in this embodiment, the skin condition-improving component can be It is possible to obtain a cosmetic that contains it in an appropriate concentration and that can efficiently exhibit the function of improving skin condition.
- the combination of the components (a) and (b) has high stability, particularly high thermal stability, and can maintain the action of the cosmetic over a long period of time. Also, the combination of component (a) and component (b) is less irritating to the skin.
- the pH of the skin-penetrating cosmetic to be obtained is maintained within a suitable range for cosmetics, that is, within a range of 4 or more and 10 or less, preferably 5 or more and 9 or less. Therefore, the cosmetic according to this embodiment is also suitable for users who are sensitive to pH.
- the ratio (m b /m a ) of the molar amount (m b ) of component ( b ) to the molar amount (m a ) of component (a) is preferably from 0.3 to 10, more preferably from 0.3 to 10. It may be 5 or more and 5 or less. When the value of the ratio is within the above range, component (a) and component (b) can be well mixed to form a stable composite solvent.
- lauryl betaine as component (a) and xylitol as component (b)
- lauryl betaine as component (a) and glycerol as component (b)
- lauryl betaine as component (a)
- erythritol as component (b)
- lauryl betaine as component (a) and 2-hydroxyethyl urea as component (b).
- the total amount of component (a) and component (b) is preferably 0.001% by mass or more and 30% by mass or less, more preferably 0.01% by mass or more and 3% by mass or less, relative to the total amount of the cosmetic. you can
- the component (a) and the component (b) are mixed in advance, and the skin condition improving component (c) is added to the mixture and dissolved. It is preferable to let Thereby, the component (c) can be well dissolved in the composite solvent, and the dissolved state can be stably maintained.
- the skin condition-improving component (c) is not particularly limited as long as it is a component that improves some condition of the skin. , moisture content improvement, hue improvement, melanin content reduction, blood circulation improvement, moisturizing, and cell activation. Among these, ingredients having a whitening action are preferably used. Moreover, component (c) is preferably a hydrophilic or water-soluble organic compound.
- component (c) amino acids or derivatives thereof, or substances classified as water-soluble vitamins, etc. are preferably used.
- component (c) include niacinamide (nicotinic acid amide), tranexamic acid, 4-methoxysalicylic acid, glycylglycine, hydroxyethylimidazolidinone (1-(2-hydroxyethyl)imidazolidin-2-one etc.), hyaluronic acid, collagen, and pyrimidylpyrazole compounds represented by the following general formula (2), such as 2-(3,5-dimethylpyrazol-1-yl)-4,6-dimethylpyrimidine, 2-( 3,5-dimethylpyrazol-1-yl)-4,5,6-trimethylpyrimidine, 5-ethyl-2-(4-ethyl-3,5-dimethylpyrazol-1-yl)-4,6-dimethylpyrimidine ), and hydrochloride salts thereof.
- Niacinamide is a component that exhibits effects such as whitening, anti-aging, and anti-wrinkle effects.
- the above ingredients may be formulated in the form of salts, preferably in the form of pharmaceutically acceptable salts such as sodium salts or potassium salts.
- the said component can be used individually or in combination of 2 or more types.
- R 1 , R 3 , R 4 and R 6 are each independently an alkyl group having 1 to 3 carbon atoms, and R 2 and R 5 are each independently a hydrogen atom or a is an alkyl group.
- the content of component (c) in the cosmetic according to this embodiment is preferably 0.00001% by mass or more and 30% by mass or less, more preferably 0.01% by mass or more and 10% by mass, relative to the total amount of the cosmetic. may be:
- the value of the ratio of the content (w c ) of component ( c) to the sum of the content (wa ) of component (a) and the content (w b ) of component (b) may be preferably from 0.00001 to 10,000, more preferably from 0.1 to 1,000 on a mass or weight basis.
- the component (c) can be well dissolved in the solvent, and the action of the component (c) can be satisfactorily exhibited.
- the combination of component (a) and component (b) promotes permeation of component (c) and improves percutaneous absorbability. In this case, not only is component (c) more likely to be taken into the skin, but retention in the skin is also improved.
- the water may be ion-exchanged water, purified water, tap water, or the like.
- the content of water in the cosmetic according to this embodiment depends on the properties of the cosmetic to be obtained, but is preferably 1% by mass or more and 100% by mass or less, more preferably 10% by mass, based on the total amount of the cosmetic. It may be more than or equal to 90% by mass or less.
- the skin-penetrating cosmetic composition according to this embodiment may contain other components other than the above components (a) to (d) within a range that does not impair the effects of this embodiment.
- the other component may be, for example, an aqueous component other than component (d) water. More specifically, they may be water-soluble alcohols, aqueous phase thickeners, humectants, chelating agents, preservatives, neutralizers, pigments, and the like.
- the water-soluble alcohol may be a lower alcohol, such as ethanol, propanol, isopropanol, isobutyl alcohol, t-butyl alcohol, and the like.
- a polyhydric alcohol can also be used as a humectant, and the polyhydric alcohol used as a humectant can be added together with water and/or aqueous components during preparation.
- the moisturizer is preferably added after dissolving the skin condition-improving component (c) described above in a solvent containing the components (a) and (b) described above.
- oily components include oily components, water-soluble polymers, surfactants other than component (a), inorganic powders, polymer powders, and the like.
- Oily components may be hydrocarbon oils, ester oils, higher fatty acids, higher alcohols, silicone oils, liquid oils, solid oils, waxes, fragrances, oil phase thickeners and the like.
- Surfactants other than component (a) may be cationic surfactants, anionic surfactants, nonionic surfactants, amphoteric surfactants other than component (a), and the like.
- the water-soluble polymer is an acrylic polymer, more specifically, a polymer containing monomer units derived from one or more of acrylic acid, methacrylic acid, acrylic acid alkyl ester, methacrylic acid alkyl ester, acrylamide, and methacrylamide, or its salt or the like.
- acrylic polymer more specifically, a polymer containing monomer units derived from one or more of acrylic acid, methacrylic acid, acrylic acid alkyl ester, methacrylic acid alkyl ester, acrylamide, and methacrylamide, or its salt or the like.
- it may be a carboxyvinyl polymer (carbomer) or the like.
- One aspect of the present invention is a method for producing a skin-penetrating cosmetic, comprising (a) an alkylbetaine-based amphoteric surfactant, and (b) 1 selected from the group consisting of polyhydric alcohols, urea, and urea derivatives.
- the method may include (d) adding water.
- the skin-penetrating cosmetic according to this embodiment can be produced at room temperature (15° C. to 25° C.).
- the skin-penetrating cosmetic according to this embodiment can be produced by heating (50° C. to 90° C.).
- one embodiment of the present invention includes (a) an alkylbetaine-based amphoteric surfactant, (b) one or more selected from the group consisting of polyhydric alcohols, urea, and urea derivatives, and (c) skin conditions.
- It may be a skin-penetrating cosmetic obtained by adding (d) water after mixing with the improving component. Furthermore, after mixing the component (a) and the component (b) to prepare a complex (complex solvent), the component (c) is dissolved in the resulting complex (complex solvent), and then (d) water is added. It is preferable that the cosmetic is obtained by
- Example 1 Percutaneous absorption test using artificial membrane (example using polyhydric alcohol) ⁇ Sample preparation> (Example 1-1) A mixture of betaine lauryldimethylaminoacetate (“Nissan Anon BL-SF” manufactured by NOF Corporation, 35% aqueous dispersion) and xylitol, and niacinamide (nicotinamide) as an active ingredient (skin condition improving ingredient) was diluted with ion-exchanged water to obtain a sample of Example 1-1.
- betaine lauryldimethylaminoacetate (“Nissan Anon BL-SF” manufactured by NOF Corporation, 35% aqueous dispersion) and xylitol
- niacinamide nicotinamide
- the above preparation was carried out so that the concentration of betaine lauryldimethylaminoacetate in the sample was 5 mM, the concentration of xylitol was 15 mM, and the concentration of niacinamide was 5% by mass.
- Example 1-2 A liquid obtained by mixing lauryldimethylaminoacetic acid betaine ("Nissan Anon BL-SF" manufactured by NOF Corporation, 35% aqueous dispersion) and the active ingredient niacinamide is diluted with ion-exchanged water. , was used as the sample of Example 1-2. The above preparation was carried out so that the concentration of betaine lauryldimethylaminoacetate was 5 mM and the concentration of niacinamide was 5% by mass in the sample.
- Example 1-3 A liquid obtained by mixing xylitol and niacinamide, which is an active ingredient, was diluted with ion-exchanged water to prepare a sample of Example 1-3. The above preparation was carried out so that the concentration of xylitol in the sample was 15 mM and the concentration of niacinamide was 5% by mass.
- the flux J (mg/cm 2 /h) of the active ingredient permeating the artificial skin was determined by differentiating the cumulative permeation amount Q obtained by the Pseudo-Newtonian method of Microsoft (registered trademark) Excel Solver with respect to time t. rice field.
- Example 1-1 As shown in FIG. 1, in the sample containing both the alkylbetaine-based amphoteric surfactant and the polyhydric alcohol (Example 1-1), the cumulative permeation amount of the active ingredient decreased to It was higher than in Examples 1-2 and 1-3). In addition, as shown in Table 1, in Example 1-1, the diffusion coefficient of the active ingredient in the skin is higher than in Examples 1-2 and 1-3, and the flux of the active ingredient is Higher than 1-3. Therefore, it was found that the combined use of an alkylbetaine-based amphoteric surfactant and a polyhydric alcohol facilitates the incorporation of the active ingredient into the skin and improves the percutaneous absorbability.
- Example 2-1 Percutaneous absorption test using artificial membrane (example using urea derivative)
- Example 2-1 Lauryldimethylaminoacetate betaine (manufactured by NOF Corporation "Nissan Anon BL-SF" 35% aqueous dispersion) and hydrovance (hydroxyethyl urea) are added to a liquid obtained by mixing niacinamide, an active ingredient. (nicotinic acid amide) was added and diluted with ethanol and ion-exchanged water to obtain a sample of Example 2-1.
- the above preparation was carried out so that the concentration of betaine lauryldimethylaminoacetate in the sample was 5 mM, the concentration of hydrobance was 15 mM, the concentration of ethanol was 10% by mass, and the concentration of nicotinamide was 5% by mass.
- Example 2-2 Niacinamide was added to betaine lauryldimethylaminoacetate (manufactured by NOF Corporation, "Nissan Anon BL-SF", 35% aqueous dispersion), diluted with ethanol and ion-exchanged water, and used as a sample of Example 2-2. .
- the above preparation was carried out so that the concentration of betaine lauryldimethylaminoacetate in the sample was 5 mM, the concentration of ethanol was 10% by mass, and the concentration of nicotinamide was 5% by mass.
- Example 2-3 Niacinamide was dissolved in ethanol and deionized water to prepare a sample for Example 2-3. The above preparation was carried out so that the concentration of ethanol was 10% by mass and the concentration of niacinamide was 5% by mass in the sample.
- a high-throughput diffusion cell manufactured by Ikeda Rika Co., Ltd., "Skin Permeability Tester Diffusion Cell Array System", effective area of membrane of each cell: 0.785 cm 2 , capacity of each receptor: 3 mL
- Strat-M® was mounted with the stratum corneum side facing the donor, and each sample was applied to the donor side at 10 ⁇ L/cm 2 .
- the receptor was filled with phosphate buffered saline (PBS) and the heater temperature was set at 39.5°C.
- PBS phosphate buffered saline
- the receptor fluid was sampled and the amount of niacinamide delivered into the receptor fluid was measured by Nanospace LC (Osaka Soda Co., Ltd.).
- the amount of niacinamide in the mixture was measured by Nanospace LC (Osaka Soda Co., Ltd.) and delivered into the artificial skin. was the amount of niacinamide added. Results are shown in FIG. FIG. 2 shows the amount of niacinamide in the receptor fluid and in the artificial skin as a percentage (mass %) relative to the amount of niacinamide in the applied sample.
- the sample containing both an alkylbetaine-based amphoteric surfactant and a polyhydric alcohol contains an alkylbetaine-based amphoteric surfactant but does not contain a polyhydric alcohol ( Example 2-2) and a sample containing neither an alkylbetaine-based amphoteric surfactant nor a polyhydric alcohol (Example 2-3), the concentration of the active ingredient in the artificial skin is increased, and the activity It was found that the retention of the ingredients in the skin was improved.
- Example 3-1 Percutaneous absorption test on human skin (Example 3-1) Lauryldimethylaminoacetate betaine (manufactured by NOF Corporation "Nissan Anon BL-SF" 35% aqueous dispersion) and a liquid obtained by mixing xylitol, the active ingredient niacinamide (nicotinamide) is added. was added and diluted with ion-exchanged water to obtain a sample of Example 3-1.
- niacinamide niacinamide
- the above preparation was carried out so that the concentration of betaine lauryldimethylaminoacetate was 5 mM and the concentration of xylitol was 15 mM in the sample (so that the total concentration of betaine lauryldimethylaminoacetate and xylitol was 25 mM), the concentration of nicotinamide was 5% by mass.
- Example 3-2 Lauryldimethylaminoacetic acid betaine ("Nissan Anon BL-SF" manufactured by NOF Corporation, 35% aqueous dispersion) and xylitol are added to the liquid obtained by mixing the active ingredient niacinamide (nicotinamide). was added and diluted with ion-exchanged water to obtain a sample of Example 3-2.
- niacinamide nicotinamide
- the above preparation was carried out so that the concentration of betaine lauryldimethylaminoacetate was 5 mM and the concentration of xylitol was 15 mM in the sample (so that the total concentration of betaine lauryldimethylaminoacetate and xylitol was 12 mM), the concentration of nicotinamide was 5% by mass.
- Example 3-3 Niacinamide (nicotinamide), which is an active ingredient, was diluted with deionized water to prepare a sample for Example 3-3. The preparation was carried out so that the concentration of niacinamide in the sample was 5% by mass.
- Example 4-1 and Example 4-4 Test using cosmetic formulation (artificial membrane) (Example 4-1 and Example 4-4) As shown in Table 2, the lotions of Examples 4-1 and 4-2 were prepared according to conventional methods. In the preparation of Example 4-2, the penetration enhancing component was mixed, and after preparation, the other remaining components were added and mixed.
- gel creams of Examples 4-3 and 4-4 were prepared according to a conventional method.
- the preparation of Example 4-4 was prepared by mixing multiple penetration enhancing ingredients and then adding and mixing the other remaining ingredients after preparation.
- samples containing alkylbetaine-based amphoteric surfactants and polyhydric alcohols contain both. It was found that the amount of niacinamide permeated into the skin was improved compared to the samples (Examples 4-1 and 4-3) which were not treated.
- the acceptor chamber was filled with 3 mL of phosphate buffered saline (PBS) and the heater temperature was set at 39.5°C.
- PBS phosphate buffered saline
- human skin was divided into stratum corneum, epidermis other than stratum corneum, and dermis, and niacinamide in each part was extracted by impregnating with water/methanol 1:1 mixture. Measured by Space LC (Osaka Soda Co., Ltd.). The results are shown in FIGS. 8 and 9.
- FIG. 8 and 9 the amount of niacinamide that permeated each site of the skin is shown as a ratio (% by mass) to the amount of niacinamide in the applied sample.
- the amount of each active ingredient extracted into the solvent was measured by liquid chromatography-mass spectrometry (LCMS) analysis, and the stratum corneum penetration rate (%) of each active ingredient was determined.
- LCMS liquid chromatography-mass spectrometry
- FIGS. 10 and 11 For potassium 4-methoxysalicylate, the ratio of the amount of 4-methoxysalicylic acid (4-MS) ionized in the solvent to the amount of potassium 4-methoxysalicylate (4-MSK) in the applied sample ( % by mass).
- Example 5-1 Experiment using different component (b) (Example 5-1)
- the liquid obtained by adding potassium 4-methoxysalicylate, which is an active ingredient, to betaine lauryldimethylaminoacetate (“Nissan Anon BL-SF” manufactured by NOF Corporation, 35% aqueous dispersion) is diluted with ion-exchanged water. and used as a sample of Example 5-1.
- the preparation was carried out so that the concentration of betaine lauryldimethylaminoacetate was 5 mM and the concentration of potassium 4-methoxysalicylate was 1 mass % in the sample.
- Example 5-2 Betaine lauryldimethylaminoacetate (“Nissan Anon BL-SF” manufactured by NOF Corporation, 35% aqueous dispersion) and xylitol are mixed to obtain a mixed solution, and the mixed solution is added with niacinamide ( nicotinic acid amide) was diluted with deionized water to obtain a sample of Example 5-2.
- the preparation was carried out so that the concentration of betaine lauryldimethylaminoacetate in the sample was 5 mM, the concentration of xylitol was 20 mM, and the concentration of potassium 4-methoxysalicylate was 1 mass %.
- Example 5-3 to Example 5-10 A sample was prepared in the same manner as in Example 5-2, replacing xylitol with component (b) shown in Table 4. Preparations were carried out so that the concentration of betaine lauryldimethylaminoacetate was 5 mM, the concentration of component (b) was 15 mM, and the concentration of potassium 4-methoxysalicylate was 1% by mass in the sample diluted with ion-exchanged water. rice field.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
Abstract
Description
成分(a)は、後述の成分(b)と組み合わせて、皮膚状態改善成分の浸透促進剤として機能する溶媒である。成分(a)は、界面活性作用を有するベタイン系化合物のうち、アルキルベタイン型のものである。より具体的には、成分(a)は、
成分(b)は、上記成分(a)と組み合わせて、皮膚状態改善成分の浸透促進剤として機能する成分である。成分(b)は、多価アルコール、尿素、若しくは尿素誘導体、又はこれらの組合せであってよい。成分(b)は、成分(a)との併用により、皮膚状態改善成分の溶媒として作用するとともに、角層流動化作用がみられ、良好な浸透促進作用を奏する。また、皮膚に対する刺激(例えば痛み、痒み、発疹、赤み等の症状として認識される、使用者によって不快な影響)も少ない又はないという利点もあり、敏感な皮膚に対しても使用できる。
上記成分(a)と上記成分(b)とは、混合した場合に分子間相互作用によって、得られる混合物の融点が大きく降下するものであってよい。例えば、両者ともに常温で固体であっても、混合することによって常温で液体又は不定形の状態(非晶質)に変化し得るものであってよい。本形態における成分(a)と成分(b)とは、組み合わせることによってコンプレックスを形成し、深共晶溶媒(Deep Eutectic Solvent;DES)、又はイオン液体(Ion Liquid;IL)と呼ばれるものを構成できる。このように複数の成分を混合することで得られた、混合前の成分の融点よりも低い融点を有する液体溶媒を複合溶媒と呼ぶ場合がある。
成分(c)である皮膚状態改善成分は、皮膚の何らかの状態を改善する成分であれば特に限定されず、美白、抗老化、抗酸化、シワ改善、シミ低減、キメ向上、ハリ向上、ツヤ向上、水分量向上、色相向上、メラニン量低減、血行状態向上、保湿、及び細胞賦活の1以上の作用を有する成分であってよい。これらのうち、主として美白作用を有する成分が好適に使用される。また、成分(c)は、親水性又は水溶性の有機化合物であると好ましい。
水は、イオン交換水、精製水、水道水等であってよい。本形態による化粧料における水の含有量は、得ようとする化粧料の性状にもよるが、化粧料の全量に対して、好ましくは1質量%以上100質量%以下、より好ましくは10質量%以上90質量%以下であってよい。
本形態による皮膚浸透用化粧料は、本形態による効果を阻害しない範囲で、上述の成分(a)~成分(d)以外のその他の成分を含有していてよい。その他の成分は、例えば成分(d)水以外の水性成分であってよい。より具体的には、水溶性アルコール、水相増粘剤、保湿剤、キレート剤、防腐剤、中和剤、色素等であってよい。
本発明の一形態は、皮膚浸透用化粧料の製造方法であって、(a)アルキルベタイン系両性界面活性剤と、(b)多価アルコール、尿素、尿素誘導体からなる群から選択される1種以上と、(c)皮膚状態改善成分とを混合した後、(d)水を添加することを含む方法であってよい。この場合、成分(a)と成分(b)とを混合してコンプレックス(複合溶媒)を調製した後、得られたコンプレックス(複合溶媒)に成分(c)を溶解することが好ましい。本形態による皮膚浸透用化粧料は、常温(15℃~25℃)で製造することができる。また、本形態による皮膚浸透用化粧料は加熱して(50℃~90℃)製造することができる。
<試料の調製>
(例1-1)
ラウリルジメチルアミノ酢酸ベタイン(日油株式会社製「ニッサンアノンBL-SF」、35%水分散体)とキシリトールとの混合液と、活性成分(皮膚状態改善成分)であるナイアシンアミド(ニコチン酸アミド)と混合して得られた液を、イオン交換水で希釈し、例1-1の試料とした。上記調製は、試料中、ラウリルジメチルアミノ酢酸ベタインの濃度が5mM、キシリトールの濃度が15mM、ナイアシンアミドの濃度が5質量%となるように行った。
ラウリルジメチルアミノ酢酸ベタイン(日油株式会社製「ニッサンアノンBL-SF」、35%水分散体)と、活性成分であるナイアシンアミドとを混合して得られた液を、イオン交換水で希釈し、例1-2の試料とした。上記調製は、試料中、ラウリルジメチルアミノ酢酸ベタインの濃度が5mM、ナイアシンアミドの濃度が5質量%となるように行った。
キシリトールと、活性成分であるナイアシンアミドと混合して得られた液を、イオン交換水で希釈し、例1-3の試料とした。上記調製は、試料中、キシリトールの濃度が15mM、ナイアシンアミドの濃度が5質量%となるように行った。
(累積透過量)
静置型フランツ拡散セル(バイオコム・システムズ社製「縦型パームセル」、膜有効面積1.77cm2:、レセプタ容量:9.6mL)に、人工皮膚(Merck KGaAより入手したStrat-M(登録商標))を、角質層側がドナー側となるように装着し、ドナー側から試料を無限用量にて1.0mL適用した。レセプタにはリン酸緩衝生理食塩水(PBS)を満たし、温水循環部の温度は35.5℃に維持した。1時間ごとにレセプタ液をサンプリングし、ナイアシンアミドの量をナノスペースLC(株式会社大阪ソーダ)によって測定し、累積透過量(mg/cm2)を求めた。
人工皮膚を透過する活性成分の流束J(mg/cm2/h)を、Microsoft(登録商標) Excel SolverのPseudo-Newtonian法により得られた累積透過量Qを時間tで微分することにより求めた。
(例2-1)
ラウリルジメチルアミノ酢酸ベタイン(日油株式会社製「ニッサンアノンBL-SF」35%水分散体)と、ハイドロバンス(ヒドロキシエチル尿素)とを混合して得られた液に、活性成分であるナイアシンアミド(ニコチン酸アミド)を添加し、エタノール及びイオン交換水で希釈し、例2-1の試料とした。上記調製は、試料中、ラウリルジメチルアミノ酢酸ベタインの濃度が5mM、ハイドロバンスの濃度が15mM、エタノールの濃度が10質量%、ニコチン酸アミドの濃度が5質量%となるように行った。
ラウリルジメチルアミノ酢酸ベタイン(日油株式会社製「ニッサンアノンBL-SF」、35%水分散体)に、ナイアシンアミドを添加し、エタノール及びイオン交換水で希釈し、例2-2の試料とした。上記調製は、試料中、ラウリルジメチルアミノ酢酸ベタインの濃度が5mM、エタノールの濃度が10質量%、ニコチン酸アミドの濃度が5質量%となるように行った。
ナイアシンアミドを、エタノール及びイオン交換水で溶解し、例2-3の試料とした。上記調製は、試料中、エタノールの濃度が10質量%、ナイアシンアミドの濃度が5質量%となるように行った。
高スループット型ディフュージョンセル(池田理化社製「皮ふ透過性試験装置 ディフュージョンセルアレイシステム」、各セルの膜の有効面積:0.785cm2、各レセプタ容量:3mL)に、人工皮膚(Merck KGaAより入手したStrat-M(登録商標))を、角質層側がドナー側となるように装着し、各試料をドナー側に10μL/cm2で適用した。レセプタにはリン酸緩衝生理食塩水(PBS)を満たし、ヒータ温度は39.5℃に設定した。4時間後、レセプタ液をサンプリングして、レセプタ液中に送達されたナイアシンアミドの量をナノスペースLC(株式会社大阪ソーダ)によって測定した。また、人工皮膚を取り外して、水/メタノール1:1混液中に終夜浸漬させた後、当該混液中のナイアシンアミドの量をナノスペースLC(株式会社大阪ソーダ)によって測定し、人工皮膚中に送達されたナイアシンアミドの量とした。結果を、図2に示す。図2には、レセプタ液中及び人工皮膚中でのナイアシンアミドの各量を、塗布された試料中のナイアシンアミドの量に対する割合(質量%)として示す。
(例3-1)
ラウリルジメチルアミノ酢酸ベタイン(日油株式会社製「ニッサンアノンBL-SF」35%水分散体)と、キシリトールとを混合して得られた液に、活性成分であるナイアシンアミド(ニコチン酸アミド)を添加し、イオン交換水で希釈し、例3-1の試料とした。上記調製は、試料中、ラウリルジメチルアミノ酢酸ベタインの濃度が5mM、キシリトールの濃度が15mMとなるように(ラウリルジメチルアミノ酢酸ベタイン及びキシリトールの合計濃度が25mMとなるように)、ニコチン酸アミドの濃度が5質量%となるように行った。
ラウリルジメチルアミノ酢酸ベタイン(日油株式会社製「ニッサンアノンBL-SF」、35%水分散体)と、キシリトールとを混合して得られた液に、活性成分であるナイアシンアミド(ニコチン酸アミド)を添加し、イオン交換水で希釈し、例3-2の試料とした。上記調製は、試料中、ラウリルジメチルアミノ酢酸ベタインの濃度が5mM、キシリトールの濃度が15mMとなるように(ラウリルジメチルアミノ酢酸ベタイン及びキシリトールの合計濃度が12mMとなるように)、ニコチン酸アミドの濃度が5質量%となるように行った。
活性成分であるナイアシンアミド(ニコチン酸アミド)をイオン交換水で希釈し、例3-3の試料とした。当該調製は、試料中、ナイアシンアミドの濃度が5質量%となるように行った。
各試料を、被験者の前腕の内側に2μL/cm2で塗布した。3時間放置した後、塗布された領域の角質層を、D-Squame(登録商標)Discs(プロモツール株式会社)を用いて15枚回収し、水/メタノール1:1混液に浸漬して、角質層中の成分を抽出した。高速液体クロマトグラフ(大阪ソーダ社製「ナノスペースLC」)によって、ナイアシンアミドを定量した。角層テープ15枚中の量を算出することで、角質層中に浸透したナイアシンアミドの量(塗布された試料中のナイアシンアミドの量に対する割合(質量%)のタンパク質1mg当たりの値)を求めた。結果を図3に示す。
(例4-1及び例4-4)
表2に示すように、例4-1及び例4-2のローションを常法にしたがって調製した。例4-2の調製は、浸透促進成分を混合し、調製した後に、他の残りの成分を添加・混合した。
静置型フランツ拡散セル(バイオコム・システムズ社製「縦型パームセル」、膜有効面積:1.77cm2、レセプタ容量:9.6mL)に、人工皮膚(Merck KGaAより入手したStrat-M(登録商標))を、角質層側がドナー側となるように装着し、ドナー側から試料を10μL/cm2(例4-1、例4-2)或いは5mg/cm2(例4-3、例4-4)適用した。レセプタにはリン酸緩衝生理食塩水(PBS)を満たし、温水循環部の温度は35.5℃に維持した。1時間ごとにレセプタ液をサンプリングし、ナイアシンアミドの量をナノスペースLC(株式会社大阪ソーダ)によって測定し、累積透過量(μg/cm2)等を求めた。結果を、図4~図7に示す。
高スループット型ディフュージョンセル(池田理化社製「皮ふ透過性試験装置 ディフュージョンセルアレイシステム」、各セルの膜の有効面積:0.785cm2、各レセプタ容量:3mL)にに、ヒト皮膚(米国 Analytical Biological Services Inc.より株式会社ケー・エー・シーを介して入手)を、角質層側がドナー側となるように装着し、各試料をドナー側に例4-1及び例4-2では10μL/cm2、例4-3及び例4-4では5mg/cm2で適用した。アクセプタチャンバにはリン酸緩衝生理食塩水(PBS)3mLを満たし、ヒータ温度は39.5℃に設定した。4時間後、ヒト皮膚を角質層、角質層以外の表皮、及び真皮に分割して、水/メタノール1:1混液に含侵することによってそれぞれの部分におけるナイアシンアミドを抽出し、その量をナノスペースLC(株式会社大阪ソーダ)によって測定した。結果を、図8及び図9に示す。なお、図8及び図9では、皮膚の各部位に浸透したナイアシンアミドの量は、適用された試料中のナイアシンアミドの量に対する割合(質量%)として示す。
表3Aに示すように、例4A-1及び例4A-2のローションを調製した。
被験者の前腕部内側をサボンドール石けん(株式会社資生堂製)を用いて洗浄した後、室温にて15分馴化させた。各試料を、3×3cm2の塗布領域に2μL/cm2で、マイクロマン(Gilson Inc., WI, USA)を用いて塗布した。3時間放置した後、皮膚表面を水道水で洗浄し、さらに、D-Squame Standard Sampling Discs(Clinical and Derm社製)を用いて、塗布領域の皮膚の角層を6枚~10枚採取した。角層剥離は、Pressure Device(Clinical and Derm社製)を用いて一定の圧力下で行った。D-Squame Standard Sampling Discsを、1枚当たり水/メタノール=1/1混液1mLに浸漬し、15分間超音波処理を行った後、37°Cの恒温槽にて一昼夜抽出を行った。溶媒中に抽出された各活性成分の量を、液体クロマトグラフィー質量分析計(LCMS)により分析することで測定し、各活性成分の角質層浸透率(%)を求めた。結果を図10及び図11に示す。なお、4-メトキシサリチル酸カリウムについては、適用された試料中の4-メトキシサリチル酸カリウム(4-MSK)の量に対する、溶媒中に電離した4-メトキシサリチル酸(4-MS)の量の割合として(質量%)表す。
(例5-1)
ラウリルジメチルアミノ酢酸ベタイン(日油株式会社製「ニッサンアノンBL-SF」、35%水分散体)に、活性成分である4-メトキシサリチル酸カリウムを添加して得られた液をイオン交換水で希釈し、例5-1の試料とした。当該調製は、試料中、ラウリルジメチルアミノ酢酸ベタインの濃度が5mM、4-メトキシサリチル酸カリウムの濃度が1質量%となるように行った。
ラウリルジメチルアミノ酢酸ベタイン(日油株式会社製「ニッサンアノンBL-SF」、35%水分散体)とキシリトールとを混合して混合液を得て、当該混合液に、活性成分であるナイアシンアミド(ニコチン酸アミド)を添加して得られた液を、イオン交換水で希釈し、例5-2の試料とした。当該調製は、試料中、ラウリルジメチルアミノ酢酸ベタインの濃度が5mM、キシリトールの濃度が20mM、4-メトキシサリチル酸カリウムの濃度が1質量%となるように行った。
キシリトールを、表4に示す成分(b)に変更し、例5-2と同様にして試料を調製した。調製は、イオン交換水で希釈した後の試料中、ラウリルジメチルアミノ酢酸ベタインの濃度が5mM、成分(b)の濃度が15mM、4-メトキシサリチル酸カリウムの濃度が1質量%となるようにそれぞれ行った。
(累積透過量)
静置型フランツ拡散セル(バイオコム・システムズ社製「縦型パームセル」、膜有効面積1.77cm2:、レセプタ容量:9.6mL)に、人工皮膚(Merck KGaAより入手したStrat-M(登録商標))を、角質層側がドナー側となるように装着し、ドナー側から試料を無限用量にて適用した。レセプタにはリン酸緩衝生理食塩水(PBS)を満たし、温水循環部の温度は35.5℃に維持した。2時間後、レセプタ液をサンプリングし、4-メトキシサリチル酸カリウムの量をナノスペースLC(株式会社オオサカソーダ)によって測定し、累積透過量(mg/cm2)を求めた。また、例5-1の累積透過量を「1」とした場合の相対値を求めた。結果を、表4及び図12に示す。
人工皮膚を透過するナイアシンアミドの透過流束(mg/cm2/h)を、累積透過量と時間の近似直線の傾きを求めることにより測定した。また、例5-1の透過流束を「1」とした場合の相対値を求めた。結果を、表4及び図13に示す。
Claims (8)
- 次の成分(a)~(d):
(a)アルキルベタイン系両性界面活性剤、
(b)多価アルコール、尿素、及び尿素誘導体からなる群から選択される1種以上、
(c)皮膚状態改善成分、並びに
(d)水
を含有する、皮膚浸透用化粧料。 - 前記成分(a)が、炭素数が10以上18以下の疎水基を有する、請求項1に記載の皮膚浸透用化粧料。
- 前記成分(a)の前記疎水基が、コレステリル基、オレイル基、イソステアリル基、ステアリル基、イソパルミチル基、ミリスチル基、ラウリル基、カプリン基、ペラルゴル基、カプリル基、カプロイル基、α-リロレニル基、ステアリル基、エイコサペンタエノイル基、及びドコサヘキサエニル基からなる群から選択される1種以上である、請求項2に記載の皮膚浸透用化粧料。
- 前記成分(b)が、グリセリン、エリスリトール、キシリトール、ソルビトール、1,3-ブチレングリコール、プロピレングリコール、ペンタンジオール、ペンチレングリコール、ヘキサンジオール、グリセロール、マルチトール、尿素、2-ヒドロキシエチル尿素、及び塩酸アルギニンからなる群から選択される1種以上である、請求項1又は2に記載の皮膚浸透用化粧料。
- 前記成分(a)のモル量に対する前記成分(b)のモル量の比の値が0.3以上10以下である、請求項1又は2に記載の皮膚浸透用化粧料。
- 前記成分(a)と前記成分(b)とがコンプレックスを形成している、請求項1又は2に記載の皮膚浸透用化粧料。
- 前記成分(a)の含有量と前記成分(b)の含有量との合計が、前記皮膚浸透用化粧料の全量に対して0.001質量%以上1質量%以下である、請求項1又は2に記載の皮膚浸透用化粧料。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023536697A JPWO2023002872A1 (ja) | 2021-07-21 | 2022-07-08 | |
CN202280044241.9A CN117545457A (zh) | 2021-07-21 | 2022-07-08 | 皮肤渗透用化妆料 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-120923 | 2021-07-21 | ||
JP2021120923 | 2021-07-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023002872A1 true WO2023002872A1 (ja) | 2023-01-26 |
Family
ID=84979211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/027174 WO2023002872A1 (ja) | 2021-07-21 | 2022-07-08 | 皮膚浸透用化粧料 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JPWO2023002872A1 (ja) |
CN (1) | CN117545457A (ja) |
WO (1) | WO2023002872A1 (ja) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002145759A (ja) * | 2000-08-28 | 2002-05-22 | Shiseido Co Ltd | 皮膚外用剤 |
JP2016222612A (ja) * | 2015-06-01 | 2016-12-28 | 昭和電工株式会社 | 化粧料または皮膚外用剤 |
-
2022
- 2022-07-08 JP JP2023536697A patent/JPWO2023002872A1/ja active Pending
- 2022-07-08 CN CN202280044241.9A patent/CN117545457A/zh active Pending
- 2022-07-08 WO PCT/JP2022/027174 patent/WO2023002872A1/ja active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002145759A (ja) * | 2000-08-28 | 2002-05-22 | Shiseido Co Ltd | 皮膚外用剤 |
JP2016222612A (ja) * | 2015-06-01 | 2016-12-28 | 昭和電工株式会社 | 化粧料または皮膚外用剤 |
Non-Patent Citations (5)
Title |
---|
DATABASE GNPD MINTEL; "Cleanse Face Wash", XP093026706, Database accession no. 980632 * |
DATABASE GNPD MINTEL; "Future Plus White Serum", XP093026705, Database accession no. 8559761 * |
DICILA: "Full ingredient list. EX Optima serum M2", COSMETIC-INFO.JP, XP009543054, Retrieved from the Internet <URL:https://www.cosmetic-info.jp/prod/detail.php?id=26653> [retrieved on 20220824] * |
OKABE, MIYOJI: "Relationship between moisturizing and moisturizing agents", FUREGURANSU JANARU - FRAGRANCE JOURNAL., FUREGURANSU JANARUSHA, TOKYO, JP, no. 2, 31 January 2015 (2015-01-31), JP , pages 102 - 103, XP009542779, ISSN: 0288-9803 * |
SHIEIDO: "HAKU Melanofocus 2", COSMETIC-INFO.JP, XP009543057, Retrieved from the Internet <URL:https://www.cosmetic-info.jp/prod/detail.php?id=8595> [retrieved on 20220824] * |
Also Published As
Publication number | Publication date |
---|---|
CN117545457A (zh) | 2024-02-09 |
JPWO2023002872A1 (ja) | 2023-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20080103099A (ko) | 외용의 의약 조성물 | |
TW200815045A (en) | Pharmaceutical compositions of ropinirole and methods of use thereof | |
KR20110121702A (ko) | 항진균제의 용해 방법 및 손발톱에 적용하기에 적합한 고농도의 항진균제를 갖는 조성물 | |
CN109846740B (zh) | 皮肤护理组合物及其制备方法和应用 | |
WO2007102090A2 (en) | Topical formulation | |
US12053481B2 (en) | Compositions and methods for deep dermal drug delivery | |
DK169121B1 (da) | Antiviralt virksom farmaceutisk olie-i-vand-emulsion indeholdende 9-[(2-hydroxyethoxy)methyl]guanin (acyclovir) eller et salt eller en ester deraf | |
JP3981074B2 (ja) | オルニチンデカルボキシラーゼインヒビターの毛包輸送のための局所用組成物 | |
WO2023002872A1 (ja) | 皮膚浸透用化粧料 | |
JP2006348000A (ja) | 皮膚外用剤 | |
EP2910254A1 (en) | Base and external preparation for skin | |
JP5125122B2 (ja) | アダパレン含有外用剤組成物 | |
JP3798927B2 (ja) | 血行促進皮膚外用剤 | |
JP2010143884A (ja) | 肌荒れ改善剤 | |
JP5670008B2 (ja) | アダパレン含有外用剤組成物 | |
WO2023085128A1 (ja) | 皮膚外用剤組成物 | |
WO2023002873A1 (ja) | 皮膚浸透用化粧料、及び皮膚浸透用化粧料の製造方法 | |
CN114504549B (zh) | 生物素的水性凝胶剂及其制备方法和应用 | |
WO2023145469A1 (ja) | 化粧料 | |
JP3625020B2 (ja) | 経皮吸収促進剤及び皮膚外用剤 | |
Rao et al. | Effect of chemical enhancers on in-vitro permeation of Losartan potassium | |
JP5646129B2 (ja) | アダパレン含有外用剤組成物 | |
KR100405920B1 (ko) | 고분자 화합물을 포함하는 화장료 조성물 | |
US20060088556A1 (en) | Topical formulation and use of buspirone | |
Lee et al. | The Effect of Limonene on Skin Permeation and Localization of Ascorbic Acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22845806 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280044241.9 Country of ref document: CN Ref document number: 2023536697 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22845806 Country of ref document: EP Kind code of ref document: A1 |